oncbrain — oncology meeting digest https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Mon, 10 Aug 2026 00:00:00 GMT Organs at Risk Radiation Dose Constraints: 2025 Update https://oncbrain.oncologytoolkit.com/2026-08-10/#oar-dose-constraints-2025 https://oncbrain.oncologytoolkit.com/2026-08-10/#oar-dose-constraints-2025 Mon, 10 Aug 2026 00:00:00 GMT safety SFRO 2025 OAR dose-constraint update: normofractionated, moderate hypofractionated and ablative tables across skull base, H&N, lung, breast, oesophagus, liver. HERO https://oncbrain.oncologytoolkit.com/2026-08-10/#hero-testosterone-recovery https://oncbrain.oncologytoolkit.com/2026-08-10/#hero-testosterone-recovery Mon, 10 Aug 2026 00:00:00 GMT prostate [Confirmatory] 90-day testosterone recovery to ≥280 ng/dL 53.9% with relugolix vs 3.2% with leuprolide after 48wk ADT. Eligible: Advanced prostate cancer, completing 48wk ADT, no ongoing ADT planned